# Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance

> **NCT04150068** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Gilead Sciences** · enrollment: 72 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** Oral Lenacapavir
- **DRUG:** Oral Lenacapavir Placebo
- **DRUG:** Subcutaneous Lenacapavir
- **DRUG:** Failing ARV Regimen
- **DRUG:** Optimized Background Regimen (OBR)

## Key facts

- **NCT ID:** NCT04150068
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-11-21
- **Primary completion:** 2020-10-05
- **Final completion:** 2027-01
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04150068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04150068, "Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT04150068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*